<産業資料/調査レポートの題名> 2022年7月19日

乳癌治療薬の世界市場2019-2023


◆英文タイトル:Global Breast Cancer Therapeutics Market 2019-2023

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Targeted therapy – Market size and forecast 2018-2023
• Hormonal therapy – Market size and forecast 2018-2023
• Chemotherapy – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
• Ductal carcinoma in situ
• Invasive Ductal Carcinoma
• Triple-negative breast cancer
• Inflammatory breast cancer
• Metastatic breast cancer
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Eli Lilly
• F. Hoffmann-La Roche
• Novartis
• Pfizer
PART 15: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global oncology drugs market
Exhibit 03: Segments of global oncology drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Molecules in the pipeline for different type of breast cancer
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Product – Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Targeted therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Targeted therapy – Year-over-year growth 2019-2023 (%)
Exhibit 23: Sales in $ millions from 2015-2017
Exhibit 24: Hormonal therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Hormonal therapy – Year-over-year growth 2019-2023 (%)
Exhibit 26: Chemotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Chemotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: First-in-class drugs for the treatment of breast cancer approved in 2017 and 2018
Exhibit 34: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 35: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 37: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: New drug approvals for breast cancer
Exhibit 43: Patient support programs
Exhibit 44: Biosimilars for Herceptin and Avastin
Exhibit 45: Impact of drivers and challenges
Exhibit 46: List of collaborations between manufacturers for the breast cancer therapies
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AstraZeneca – Vendor overview
Exhibit 53: AstraZeneca – Business segments
Exhibit 54: AstraZeneca – Organizational developments
Exhibit 55: AstraZeneca – Geographic focus
Exhibit 56: AstraZeneca – Key offerings
Exhibit 57: Eli Lilly – Vendor overview
Exhibit 58: Eli Lilly – Business segments
Exhibit 59: Eli Lilly – Organizational developments
Exhibit 60: Eli Lilly – Geographic focus
Exhibit 61: Eli Lilly – Segment focus
Exhibit 62: Eli Lilly – Key offerings
Exhibit 63: F. Hoffmann-La Roche – Vendor overview
Exhibit 64: F. Hoffmann-La Roche – Business segments
Exhibit 65: F. Hoffmann-La Roche – Organizational developments
Exhibit 66: F. Hoffmann-La Roche – Geographic focus
Exhibit 67: F. Hoffmann-La Roche – Segment focus
Exhibit 68: F. Hoffmann-La Roche – Key offerings
Exhibit 69: Novartis – Vendor overview
Exhibit 70: Novartis – Business segments
Exhibit 71: Novartis – Organizational developments
Exhibit 72: Novartis – Geographic focus
Exhibit 73: Novartis – Segment focus
Exhibit 74: Novartis – Key offerings
Exhibit 75: Pfizer – Vendor overview
Exhibit 76: Pfizer – Business segments
Exhibit 77: Pfizer – Organizational developments
Exhibit 78: Pfizer – Geographic focus
Exhibit 79: Pfizer – Segment focus
Exhibit 80: Pfizer – Key offerings
Exhibit 81: Validation techniques employed for market sizing
Exhibit 82: List of abbreviations


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark